Dr. Joseph Pantginis

H.C. Wainwright & Co.

Image: Dr. Joseph Pantginis

Joseph Pantginis, Ph.D., joined H.C. Wainwright as Managing Director covering Biotechnology. Dr. Pantginis has over 15 years of sell-side experience covering biotechnology companies, having spent most of those years at ROTH Capital Partners and Canaccord Adams. Prior to his sell-side career, he worked at Regeneron Pharmaceuticals, where he founded the Retrovirus Core Facility, providing molecular biology service and retroviral vectors to a broad range of Regeneron's research programs. His therapeutic focus is oncology, as well as regenerative medicine and gene therapy. He is also widely recognized for his expertise in cancer immunotherapy as a therapeutic approach to treating cancer. Dr. Pantginis received a B.S. in Biology from Fordham University, an M.B.A. in finance from Pace University, and a Ph.D. in Molecular Genetics from the Albert Einstein College of Medicine.

Recent Articles

Target Price Boosted 400% on Biopharma Co. 12/27/2022

The immunotherapy developer also announced positive initial results from the VITALIZE trial in diffuse large B cell lymphoma, noted an H.C. Wainwright & Co. report.

Biopharma Co. Shows Large Potential Return 10/21/2022

Palatin Technologies Inc.'s third-party clinical trial of Vyleesi in women with hypoactive sexual desire disorder was just published in the Journal of Clinical Investigation, and the biopharma offers investors significant potential return, noted an H.C. Wainwright & Co. report.

Biotech Co.'s Target Price Over Three Times Current 10/13/2022

Expanded interim data from the Phase 2 trial of this biotech's lead asset PDS0101 in HPV16-associated cancers are consistent with previously reported results from the same study. Read more to discover why H.C Wainright & Co. believes this stock is a Buy with a target price over three times the current.

Biopharma Co. Partners With Merck for Combo Drug Trial 10/12/2022

With this and other clinical studies, the U.S. company has a busy and, thus, catalyst-rich Q4/22 ahead, noted an H.C. Wainwright & Co. report.

Co.'s Clinical Program in HPV+ Cancers Gives It a Buy Rating 09/23/2022

To fund continued development of its lead immunotherapy candidate, the U.S.-based biopharma recently completed a $35 million debt financing agreement, noted an H.C. Wainwright & Co. report.


Recent Quotes

"It is an opportune time to explore the investment case of ATNM based on the late stage nature of the lead asset, addressing unmet medical needs, clinical data in hand, and a broad set of upcoming catalysts."

— Dr. Joseph Pantginis, ROTH Capital Partners (10/31/16)
more >

"It is an opportune time to explore the investment case of ATNM based on the late stage nature of the lead asset, addressing unmet medical needs, clinical data in hand, and a broad set of upcoming catalysts."

— Dr. Joseph Pantginis, ROTH Capital Partners (10/18/16)
more >

"ATNM the expected initiation of the Phase II study with Actimab-A in AML patients."

— Dr. Joseph Pantginis, ROTH Capital Partners (9/27/16)
more >

"We are initiating coverage of ATNM with a Buy rating."

— Dr. Joseph Pantginis, ROTH Capital Partners (8/24/16)
more >

"IMNP licensed worldwide rights to Amiket and Amiket Nano to Novel Pain Therapeutics."

— Dr. Joseph Pantginis, ROTH Capital Partners (5/16/16)
more >

"IMNP's lead driver is bertilimumab; one application has the potential for significantly increased visibility: atopic dermatitis."

The Life Sciences Report Interview with Joe Pantginis (4/27/16)
more >

"The interim data from the Phase 1a/1b studies of Supinoxin and RX-3117 will really increase the visibility for RNN this year."

The Life Sciences Report Interview with Joseph Pantginis (4/27/16)
more >

"Milestones for IMNP in 2016 include Phase 2 data for bullous pemphigoid and ulcerative colitis studies."

— Dr. Joseph Pantginis, ROTH Capital Partners (4/4/16)
more >



Due to permission requirements, not all quotes are shown.